Monopar Therapeutics initiated with an Overweight at Piper Sandler

Piper Sandler initiated coverage of Monopar Therapeutics (MNPR) with an Overweight rating and $72 price target The firm thinks Monopar’s two distinct therapeutic pursuits represent value potential far exceeding the company’s current market cap. While these two programs – radiotherapeutics utilizing a unique new oncology target and a small molecule copper mobilizer with “impressive” proof of concept data in Wilson disease – “are quite disparate,” they collectively represent meaningful upside to current levels, the analyst tells investors in a research note.